AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read$CELC

Celcuity Inc. (CELC) Appoints David W. Gryska to Board

Celcuity Inc. (CELC) has added David W. Gryska to its Board of Directors, a move coinciding with its transition to the commercial stage following FDA approval of its drug REVTORPYK.

Original reporting
tradingview.com
Published Oct 2, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Celcuity Inc. (CELC) Appoints David W. Gryska to Board — source image
Source · tradingview.com
Decision brief

The 30-second read

$CELCNeutralLow
01

Why it matters

The board appointment is a routine governance update but underscores the company's move toward commercialization.

02

Market read

Minor relevance; investors may note the governance change but no immediate catalyst for price action.

03

What to watch

The appointment could signal upcoming strategic partnerships or financing.

Relevance 5/10Novelty 5/10Timing: today

Background

Celcuity recently received FDA approval for its REVTORPYK therapy and is transitioning to commercial operations.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity Inc. appointed David W. Gryska to its Board of Directors.

Expected impact

modest upside as investors may view the appointment positively

Evidence & confidence

New director adds experience; no immediate financial impact but could support future milestones.

Market effects

Sector

None significant; governance change does not affect sector dynamics.

Regional

Limited to U.S. biotech investors.

Global

Low; micro‑cap news with minimal broader impact.

Counterpoint

What could challenge this read

Board addition may not translate into near‑term price movement.

Key entities

  • Company
    Celcuity Inc.

    Biotech firm advancing REVTORPYK therapy.

  • Person
    David W. Gryska

    New board member.

Read at source← All news

Related articles

OCT 23
$CELCMedAI 8/10

Celcuity reports phase 1b prostate cancer trial results

Celcuity Inc. (CELC) reported Phase 1b/2 trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer. The study showed median radiographic progression-free survival of 15.7 months for patients who received prior abiraterone and 9.1 months for those who received prior enzalutamide. The company plans to begin the Phase 2 portion of the study in the first half of 2027.

investing.com2 min
OCT 22
High

Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data

Celcuity Inc. shares rose 7.78% after Cantor Fitzgerald initiated coverage with an overweight rating and a $140 price target, citing growth potential of its breast cancer drug, Revtorpyk. The company will present key clinical data at the ESMO Congress this weekend. Analysts are bullish, with price targets ranging from $130 to $177, despite a 50% stock decline over six months.

ibtimes.com.au2 min
OCT 3
$CELCMed

How REVTORPYK Launch Will Impact Celcuity (CELC) Investors

Celcuity (CELC) launched REVTORPYK in the US for certain breast cancer patients and filed an FDA application to expand its use. The company is investing in access infrastructure, and investors will watch early prescription trends and FDA review progress. Celcuity's consensus revenue and earnings forecasts for 2029 are US$817.9 million and US$267.5 million, respectively, up from current losses. The appointment of David W. Gryska to the board may impact financial oversight and execution.

simplywall.st2 min